Stepwise genetic approach for the diagnosis of primary ciliary dyskinesia in highly consanguineous populations.

Paediatrics Respiratory Medicine

Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
31 Jan 2024
Historique:
received: 05 06 2023
accepted: 16 01 2024
medline: 1 2 2024
pubmed: 1 2 2024
entrez: 31 1 2024
Statut: aheadofprint

Résumé

The American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia (PCD) consider the presence of a bi-allelic pathogenic variant confirmatory for the diagnosis of PCD, with genetic testing recommended when other confirmatory diagnostic tests are less accessible. We present our experience with genetic testing as first line with a proposed algorithm for high consanguinity populations. Patients with a suspected diagnosis of PCD underwent genetic testing according to a diagnostic algorithm composed of three steps: (1) patients with a previously known causative familial/Bedouin tribal pathogenic variant completed direct testing for a single variant; (2) if the initial test was negative or there was no known pathogenic variant, a PCD genetic panel was completed; (3) if the panel was negative, whole exome sequencing (WES) was completed. Since the implementation of the protocol, diagnosis was confirmed by genetic testing in 21 patients. The majority of them were of Bedouin origin (81%) and had a positive history of consanguinity (65%). Nine patients (43%) had a sibling with a confirmed diagnosis. Most patients (15/21, 71%) were diagnosed by direct pathogenic variant testing and the remainder by genetic panel (19%) and WES (10%). Disease-causing variants were found in nine genes, with In highly consanguineous regions, a stepwise genetic testing approach is recommended. This approach may be particularly useful in areas where the ability to obtain confirmatory diagnostic tests through other modalities is less accessible.

Sections du résumé

BACKGROUND BACKGROUND
The American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia (PCD) consider the presence of a bi-allelic pathogenic variant confirmatory for the diagnosis of PCD, with genetic testing recommended when other confirmatory diagnostic tests are less accessible. We present our experience with genetic testing as first line with a proposed algorithm for high consanguinity populations.
METHODS METHODS
Patients with a suspected diagnosis of PCD underwent genetic testing according to a diagnostic algorithm composed of three steps: (1) patients with a previously known causative familial/Bedouin tribal pathogenic variant completed direct testing for a single variant; (2) if the initial test was negative or there was no known pathogenic variant, a PCD genetic panel was completed; (3) if the panel was negative, whole exome sequencing (WES) was completed.
RESULTS RESULTS
Since the implementation of the protocol, diagnosis was confirmed by genetic testing in 21 patients. The majority of them were of Bedouin origin (81%) and had a positive history of consanguinity (65%). Nine patients (43%) had a sibling with a confirmed diagnosis. Most patients (15/21, 71%) were diagnosed by direct pathogenic variant testing and the remainder by genetic panel (19%) and WES (10%). Disease-causing variants were found in nine genes, with
CONCLUSIONS CONCLUSIONS
In highly consanguineous regions, a stepwise genetic testing approach is recommended. This approach may be particularly useful in areas where the ability to obtain confirmatory diagnostic tests through other modalities is less accessible.

Identifiants

pubmed: 38296613
pii: archdischild-2023-325921
doi: 10.1136/archdischild-2023-325921
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Dvir Gatt (D)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel dvirgatt@gmail.com.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Inbal Golan Tripto (I)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Eran Levanon (E)

Ben-Gurion University of the Negev, Beer Sheva, Israel.

Noga Arwas (N)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Guy Hazan (G)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Soliman Alkrinawi (S)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.

Aviv D Goldbart (AD)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Micha Aviram (M)

Pediatric Pulmonary Unit, Soroka Medical Center, Beer Sheva, Southern, Israel.
Ben-Gurion University of the Negev, Beer Sheva, Israel.

Classifications MeSH